Covid-19 vaccines—immunity, variants, boosters

DH Barouch - New England Journal of Medicine, 2022 - Mass Medical Soc
Covid-19 Vaccines — Immunity, Variants, Boosters | New England Journal of Medicine Skip to
main content The New England Journal of Medicine homepage Advanced Search SEARCH …

COVID-19 vaccine development: milestones, lessons and prospects

M Li, H Wang, L Tian, Z Pang, Q Yang… - Signal transduction and …, 2022 - nature.com
With the constantly mutating of SARS-CoV-2 and the emergence of Variants of Concern
(VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 …

Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months

EG Levin, Y Lustig, C Cohen, R Fluss… - … England Journal of …, 2021 - Mass Medical Soc
Background Despite high vaccine coverage and effectiveness, the incidence of symptomatic
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …

Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients

VG Hall, VH Ferreira, T Ku, M Ierullo… - … England Journal of …, 2021 - Mass Medical Soc
A Third Vaccine Dose in Organ-Transplant Recipients It is known that people receiving
immune suppressive therapy, such as recipients of solid-organ transplants, have a …

Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients

N Kamar, F Abravanel, O Marion, C Couat… - … England Journal of …, 2021 - Mass Medical Soc
Three Covid-19 Vaccine Doses in Transplant Recipients Solid-organ transplant recipients
receiving immunosuppressive therapy appear to have a poor response to Covid-19 …

Long-term survival after kidney transplantation

S Hariharan, AK Israni… - New England Journal of …, 2021 - Mass Medical Soc
Long-Term Survival after Kidney Transplantation This review discusses demographics,
survival, and risks in kidney transplantation since the mid-1990s. It addresses postoperative …

Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study

P Deepak, W Kim, MA Paley, M Yang… - Annals of internal …, 2021 - acpjournals.org
Background: Patients with chronic inflammatory disease (CID) treated with
immunosuppressive medications have increased risk for severe COVID-19. Although mRNA …

Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series

WA Werbel, BJ Boyarsky, MT Ou… - Annals of internal …, 2021 - acpjournals.org
Background: The antibody response after 2 doses of an mRNA vaccine against SARS-CoV-
2 is excellent in the general population (1), but the response is different in recipients of solid …

Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

RT Shroff, P Chalasani, R Wei, D Pennington… - Nature medicine, 2021 - nature.com
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have
shown high efficacy, but immunocompromised participants were excluded from controlled …

Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US

J Sun, Q Zheng, V Madhira, AL Olex… - JAMA internal …, 2022 - jamanetwork.com
Importance Persons with immune dysfunction have a higher risk for severe COVID-19
outcomes. However, these patients were largely excluded from SARS-CoV-2 vaccine …